Clinical investigations have demonstrated a correlation between sLOX-1 levels and the severity of atherosclerosis in patients with suspected CAD [16], reinforcing its relevance as a predictive biomarker in CVD management. This evidence concerns the gene OLR1 and atherosclerosis.